WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 406405

CAS#: 669764-17-4

Description: SU11606 is a potent c-MET inhibitor with potential anticancer activity.

Price and Availability




SU11606 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to to inquire quote.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 406405
Name: SU11606
CAS#: 669764-17-4
Chemical Formula: C29H33ClN4O4S
Exact Mass: 568.1911
Molecular Weight: 569.11472
Elemental Analysis: C, 61.20; H, 5.84; Cl, 6.23; N, 9.84; O, 11.25; S, 5.63

Synonym: SU11606; SU 11606; SU11606.

IUPAC/Chemical Name: (Z)-N-(3-chlorophenyl)-3-((3,5-dimethyl-4-(3-morpholinopropyl)-1H-pyrrol-2-yl)methylene)-N-methyl-2-oxoindoline-5-sulfonamide

SMILES Code: O=S(C1=CC2=C(NC(/C2=C\C3=C(C)C(CCCN4CCOCC4)=C(C)N3)=O)C=C1)(N(C5=CC=CC(Cl)=C5)C)=O

Technical Data

yellow solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:

Additional Information



1. Golub, Todd; Straussman, Ravid. Methods of treating cancer using a chemotherapeutic agent with an agent that blocks the activity of hepatocyte growth factor or its cognate receptor c-MET. From PCT Int. Appl. (2012), WO 2012178038 A1 20121227.

2. Smith, David; Hussain, Maha. Dual inhibitors of Met and VEGF for the treatment of castration resistant prostate cancer and osteoblastic bone metastases. PCT Int. Appl. (2012), WO 2012044577 A1 20120405

3. Comoglio, Paolo Maria; Vigna, Elisa; Giordano, Silvia. Use of monoclonal antibody (AntiMET-R) directed against hepatocyte growth factor receptor (HGFR) for the treatment and diagnosis of tumors. PCT Int. Appl. (2007), WO 2007090807 A1 20070816.

4. Tang, Peng Cho; Liang, Congxin; Miller, Todd; Lipson, Kenneth E. Preparation of 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors. U.S. Pat. Appl. Publ. (2004), US 20040204407 A1 20041014

5. Wang, Xueyan; Le, Phuong; Liang, Congxin; Chan, Julie; Kiewlich, David; Miller, Todd; Harris, Dave; Sun, Li; Rice, Audie; Vasile, Stefan; et al. Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion. Molecular Cancer Therapeutics (2003), 2(11), 1085-1092.